Skip to main content
NeuroStim Solutions logo

NeuroStim Solutions

United StatesSee on the mapFounded 2025

  • Neuromodulation
  • Series B

NeuroStim Solutions provides hands-on strategic and interim leadership for neuromodulation start-ups and scale-ups. Led by Dave Mugan, it helps companies turn complex science into credible clinical, regulatory, fundraising, and commercial strategies, drawing on more than 20 years of neuromodulation experience.

Raised
$123M
Nov 2026
Series B
Investors
6
Founded
2025
Employees
0–1

reccy insights

Recent highlights

NeuroStim Solutions is described as providing hands-on strategic and interim leadership to neuromodulation start-ups and scale-ups, led by founder Dave Mugan. The company’s stated experience includes more than 20 years in neuromodulation, work spanning first-in-human studies through regulatory approval, and expertise across clinical, regulatory, fundraising, and commercial strategy. Its funding history includes a $1,756,454 grant dated Jul 15, 2023, a $5,802,221 Series A dated Oct 13, 2023, and a separate $10 million undisclosed round on that same date. A $105 million Series B dated Nov 11, 2026 lists Perceptive Advisors, RTW Investments, Janus Henderson Investors, Affinity Asset Advisors, and Google Ventures as lead investors. There is also a notable identity and financial-data inconsistency: the company profile is named NeuroStim Solutions, while financial information uses the name Scion NeuroStim, and the stated $10 million total does not reconcile with the listed rounds. The shared website domain supports a connection, but the discrepancy warrants caution.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes NeuroStim Solutions distinct

  1. 01More than 20 years of experience dedicated to neuromodulation.
  2. 02Supports companies from early concepts and first-in-human studies through regulatory approval and early commercialisation.
  3. 03Combines clinical, regulatory, fundraising, and commercial expertise in a practical, hands-on advisory approach.
  4. 04Founder Dave Mugan has led first-in-human clinical and basic science programmes and is described as an author of peer-reviewed publications and a named inventor on multiple patents.
  5. 05Emphasizes clear, evidence-grounded communication rather than hype.

Funding

$123M disclosed
6 investors

Investors6

Also backed by
  • Affinity Asset Advisors

Similar companies

About NeuroStim Solutions

Leadership
Dave Mugan
Focus areas
NeuroTechnology, medical devices, clinical research, neuromodulation, clinical strategy, regulatory strategy, fundraising advisory, commercialisation
Headquarters
United States
Founded
2025
Employees
0–1